{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '41', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '2', 'INTRODUCTION', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Subsections 2.1 Study Rationale and 2.2 Background are based on the', 'original study design and have been left unchanged for reference.', '2.1', 'Study Rationale', 'The global incidence of lung cancer was 1.8 million in 2012, resulting in an estimated', '1.6 million deaths [World Health Organization 2012]. In the United States, the 2018', 'estimated incidence of new diagnoses was 234,030, and the estimated number of deaths was', '154,050 [National Cancer Institute 2018]. NSCLC represents approximately 80% to 85% of', 'all lung cancers. Of patients with NSCLC, tumor histology is approximately 40% to 60%', 'adenocarcinoma, 10% to 15% squamous, 5% neuroendocrine, and the rest, not otherwise', 'specified [Sulpher, J. A., et al 2013].', 'Approximately 80% of patients with NSCLC have advanced disease not amenable to surgical', 'resection at the time of diagnosis. The 5-year relative survival for patients with any lung', 'cancer overall and metastatic lung cancer specifically has been reported to be 18.6% and', '4.7%, respectively [National Cancer Institute 2018].', 'Pembrolizumab monotherapy is the current standard of care (SOC) for the treatment of', 'patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', 'and previously untreated advanced or metastatic NSCLC with programmed cell death', 'ligand 1 (PD-L1) TPS >50% and with no epidermal growth factor receptor (EGFR) or', 'anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approximately 30% of', 'patients with newly diagnosed, advanced NSCLC highly express PD-L1 with a TPS >50%', '[Reck, M., et al 2016].', 'KEYNOTE-024, a Phase 3, randomized, open-label study, compared pembrolizumab', 'monotherapy to standard first-line (1L) platinum-doublet therapy in 305 previously untreated', 'participants with advanced NSCLC and PD-L1 TPS >50%. Results from KEYNOTE-024', 'indicated a significant PFS benefit for pembrolizumab over platinum-doublet therapy, with a', 'hazard ratio (HR) of 0.50 (95% confidence interval [CI], 0.37-0.68 p<0.001). Median PFS', 'was 10.3 months (95% CI, 6.7 months to not reached) with pembrolizumab and 6.0 months', '(95% CI, 4.2-6.2 months) with platinum-doublet. Additionally, there was an os benefit, with', 'an HR of 0.60 (95% CI, 0.41-0.89; p=0.005); median os was not reached in either treatment', 'arm. The Kaplan-Meier estimates showed 80.2% (95% CI, 72.9%-85.7%) of participants', 'treated with pembrolizumab and 72.4% (95% CI, 64.5%-78.9%) of participants treated with', 'platinum-doublet therapy were alive at 6 months. Furthermore, the ORR was higher in the', 'pembrolizumab arm than in the platinum-doublet arm (44.8% VS 27.8%, respectively) [Reck,', 'M., et al 2016].', 'The results from KEYNOTE-024 established pembrolizumab as 1L therapy for patients', 'whose tumors have a TPS >50% with no EGFR or ALK genomic tumor aberrations.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '42', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Additionally, KEYNOTE-042, a randomized, open-label, Phase 3 study, compared', 'pembrolizumab monotherapy to SOC platinum-based chemotherapy in previously untreated', 'participants with advanced or metastatic NSCLC whose tumors express PD-L1 TPS 1%,', 'confirmed the os treatment effect of pembrolizumab monotherapy observed in participants', 'with TPS >50% NSCLC in KEYNOTE-024, and extended these benefits to a broader', 'population with TPS >1% NSCLC. Results from KEYNOTE-042 indicated a significant os', 'benefit for pembrolizumab over platinum-doublet therapy, with an HR of 0.81 (95% CI,', '0.71-0.93, p=0.0018). Median OS was 16.7 months (95% CI, 13.9-19.7 months) with', 'pembrolizumab and 12.1 months (95% CI, 11.3-13.3 months) with platinum-doublet [Lopes,', 'G., et al 2018]. The Kaplan-Meier estimates showed 39.3% of participants treated with', 'pembrolizumab and 28.0% of participants treated with platinum-doublet therapy were alive', 'at 6 months (data on file).', 'While the benefits observed in KEYNOTE-024 (in participants with advanced or metastatic', 'NSCLC whose tumors expressed PD-L1 TPS 50%) and KEYNOTE-042 (in participants', 'with advanced or metastatic NSCLC whose tumors expressed PD-L1 TPS 1%) were', 'substantial for these participants with NSCLC, the benefits may be improved further in', 'metastatic NSCLC with PD-L1 TPS >1% population, possibly through the combination of', 'pembrolizumab with other therapies such as lenvatinib, a multiple RTKi with a potentially', 'differentiated profile.', 'Lenvatinib has been studied as both monotherapy and in combination with chemotherapy for', 'the treatment of advanced NSCLC. As a single agent, a randomized Phase 2 study of', 'lenvatinib versus placebo was conducted in 135 participants with locally advanced or', 'metastatic nonsquamous NSCLC who had failed to respond to at least 2 systemic anticancer', 'regimens. Eighty-nine participants received 24 mg of lenvatinib QD and 46 received placebo;', 'all participants received best supportive care in addition to study intervention. Median os', 'was 38.4 weeks for lenvatinib and 24.1 weeks for placebo, median PFS was 20.9 weeks for', 'lenvatinib and 7.9 weeks for placebo, ORR was 10.1% for lenvatinib and 2.2% for placebo,', 'and the disease control rate (DCR) was 42.7% for lenvatinib and 19.6% for placebo. Grade 3', 'and/or 4 AEs occurred in 69% of lenvatinib recipients and 50% of placebo recipients. Grade', '3 and/or 4 AEs were dyspnea and pneumonia in both treatment groups, as well as', 'hypertension in the lenvatinib group [Havel, L., et al 2014].', 'Lenvatinib was studied in combination with chemotherapy in a multicenter, open-label,', 'Phase 1, dose-finding study (Study E7080-J081-110 This study, conducted in Japanese', 'participants with chemotherapy-na\u00efve NSCLC, investigated lenvatinib in combination with', 'carboplatin/paclitaxel to establish the maximum tolerated dose (MTD). The MTD of', 'lenvatinib was determined to be 4 mg BID after dose-limiting toxicities (DLTs) were', 'experienced at 6 mg BID (febrile neutropenia, gingival infection [n=2]). A dose-expansion', 'cohort was added and 28 participants were dosed in total: 12 in the dose-finding cohort and', '16 participants in the dose-expansion cohort. In total, 22 participants were dosed at 4 mg BID', 'with 6 at 6 mg BID. The ORR was 61% (95% CI: 41%, 79%) and comprised 1 CR and', '16 partial responses (PRs). The median PFS was reported as 9 months. Of the 22 participants', 'in the 4-mg BID dose level, the most frequently reported AEs were thrombocytopenia,', 'neutropenia, leukopenia, peripheral sensory neuropathy, arthralgia, and alopecia. The most', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}